An open-label, single-arm pilot study to evaluate the efficacy of daily low dose tadalafil on depression in patients with erectile dysfunction.
Brain-derived neurotrophic factor (BDNF)
depression
phosphodiesterase (PDE)
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
entrez:
7
12
2019
pubmed:
7
12
2019
medline:
7
12
2019
Statut:
ppublish
Résumé
Many studies have reported not only that depression and antidepressant medications can cause erectile dysfunction (ED), but also that having ED may increase the risk of depression. We investigated the effect of a daily low dose of a phosphodiesterase (PDE) type 5 inhibitor (tadalafil, 5 mg) on depression and levels of brain-derived neurotrophic factor (BDNF) in patients with ED. Ten male patients with at least a 3-month history of ED [International Index of Erectile Function (IIEF)-5 score ≤21] and depression [the Korean version of the Patient Health Questionnaire (PHQ)-9 score ≥5] were analyzed in this study. The subjects were prescribed a low dose of a PDE5 inhibitor (tadalafil 5 mg) once daily for 8 weeks. The survey questionnaires were performed using the PHQ-15 and the PHQ-9 before and after administration of 8 weeks of tadalafil. Blood samples used for measuring serum BDNF levels were taken and measured at baseline and after 8 weeks of treatment. The mean changes in the PHQ-9 and PHQ-15 scores were 3.60±3.27 and 2.00±2.98, respectively. Analyses of the mean changes in the PHQ-9 scores revealed that the depressive symptoms of the subjects were significantly improved after administration of eight weeks of tadalafil (P<0.05). And, there was also a statistically significant increase in the PHQ-15 scores (P<0.05). Serum levels of BDNF were higher after tadalafil treatment compared to before treatment; however, this difference was not statistically significant. The results of this prospective, clinical study suggest that daily low dose tadalafil may have a potential role in the treatment of depression in patients with ED.
Sections du résumé
BACKGROUND
BACKGROUND
Many studies have reported not only that depression and antidepressant medications can cause erectile dysfunction (ED), but also that having ED may increase the risk of depression. We investigated the effect of a daily low dose of a phosphodiesterase (PDE) type 5 inhibitor (tadalafil, 5 mg) on depression and levels of brain-derived neurotrophic factor (BDNF) in patients with ED.
METHODS
METHODS
Ten male patients with at least a 3-month history of ED [International Index of Erectile Function (IIEF)-5 score ≤21] and depression [the Korean version of the Patient Health Questionnaire (PHQ)-9 score ≥5] were analyzed in this study. The subjects were prescribed a low dose of a PDE5 inhibitor (tadalafil 5 mg) once daily for 8 weeks. The survey questionnaires were performed using the PHQ-15 and the PHQ-9 before and after administration of 8 weeks of tadalafil. Blood samples used for measuring serum BDNF levels were taken and measured at baseline and after 8 weeks of treatment.
RESULTS
RESULTS
The mean changes in the PHQ-9 and PHQ-15 scores were 3.60±3.27 and 2.00±2.98, respectively. Analyses of the mean changes in the PHQ-9 scores revealed that the depressive symptoms of the subjects were significantly improved after administration of eight weeks of tadalafil (P<0.05). And, there was also a statistically significant increase in the PHQ-15 scores (P<0.05). Serum levels of BDNF were higher after tadalafil treatment compared to before treatment; however, this difference was not statistically significant.
CONCLUSIONS
CONCLUSIONS
The results of this prospective, clinical study suggest that daily low dose tadalafil may have a potential role in the treatment of depression in patients with ED.
Identifiants
pubmed: 31807426
doi: 10.21037/tau.2019.08.24
pii: tau-08-05-501
pmc: PMC6842774
doi:
Types de publication
Journal Article
Langues
eng
Pagination
501-506Commentaires et corrections
Type : CommentIn
Informations de copyright
2019 Translational Andrology and Urology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The study was sponsored by Hanmi Pharm Co., Ltd.
Références
Drug Discov Today. 2007 Oct;12(19-20):870-8
pubmed: 17933689
Compr Psychiatry. 2008 Mar-Apr;49(2):218-23
pubmed: 18243897
Ann Med. 2009;41(3):177-85
pubmed: 18932104
Int J Impot Res. 2014 Mar-Apr;26(2):76-80
pubmed: 24285284
Int J Impot Res. 2004 Jun;16 Suppl 1:S4-7
pubmed: 15224127
Neurosci Lett. 2011 Jan 13;488(1):26-30
pubmed: 21056623
J Sex Med. 2005 Jan;2(1):109-16
pubmed: 16422913
Learn Mem. 2003 Mar-Apr;10(2):86-98
pubmed: 12663747
Int Clin Psychopharmacol. 2011 May;26(3):151-8
pubmed: 21471773
J Sex Med. 2018 Aug;15(8):1073-1082
pubmed: 29960891
Curr Neuropharmacol. 2011 Dec;9(4):715-27
pubmed: 22654729
Prog Neurobiol. 2007 Apr;81(5-6):294-330
pubmed: 17379385
Metab Brain Dis. 2014 Sep;29(3):673-82
pubmed: 24705918
J Gen Intern Med. 1998 Mar;13(3):159-66
pubmed: 9541372
J Urol. 2007 Feb;177(2):669-73
pubmed: 17222655
Am J Psychiatry. 2006 Jan;163(1):79-87
pubmed: 16390893
Psychosom Med. 2002 Mar-Apr;64(2):258-66
pubmed: 11914441
Front Psychiatry. 2018 Jan 17;8:308
pubmed: 29387021
Int J Cardiol. 2010 Feb 4;138(3):277-80
pubmed: 18789827
Psychosomatics. 2009 Nov-Dec;50(6):580-5
pubmed: 19996228
J Sex Med. 2015 Mar;12(3):804-12
pubmed: 25475605
Am J Psychiatry. 2001 Oct;158(10):1623-30
pubmed: 11578994
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
JAMA. 1999 Feb 10;281(6):537-44
pubmed: 10022110
Ther Clin Risk Manag. 2008 Dec;4(6):1315-30
pubmed: 19337438